Cargando…
Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy
BACKGROUND: Despite the increased demand for pharmacogenetic (PGx) testing to guide antidepressant use, little is known about how to implement testing in clinical practice. Best–worst scaling (BWS) is a stated preferences technique for determining the relative importance of alternative scenarios and...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107643/ https://www.ncbi.nlm.nih.gov/pubmed/35568931 http://dx.doi.org/10.1186/s43058-022-00300-7 |
_version_ | 1784708527380496384 |
---|---|
author | Salloum, Ramzi G. Bishop, Jeffrey R. Elchynski, Amanda L. Smith, D. Max Rowe, Elizabeth Blake, Kathryn V. Limdi, Nita A. Aquilante, Christina L. Bates, Jill Beitelshees, Amber L. Cipriani, Amber Duong, Benjamin Q. Empey, Philip E. Formea, Christine M. Hicks, J. Kevin Mroz, Pawel Oslin, David Pasternak, Amy L. Petry, Natasha Ramsey, Laura B. Schlichte, Allyson Swain, Sandra M. Ward, Kristen M. Wiisanen, Kristin Skaar, Todd C. Van Driest, Sara L. Cavallari, Larisa H. Tuteja, Sony |
author_facet | Salloum, Ramzi G. Bishop, Jeffrey R. Elchynski, Amanda L. Smith, D. Max Rowe, Elizabeth Blake, Kathryn V. Limdi, Nita A. Aquilante, Christina L. Bates, Jill Beitelshees, Amber L. Cipriani, Amber Duong, Benjamin Q. Empey, Philip E. Formea, Christine M. Hicks, J. Kevin Mroz, Pawel Oslin, David Pasternak, Amy L. Petry, Natasha Ramsey, Laura B. Schlichte, Allyson Swain, Sandra M. Ward, Kristen M. Wiisanen, Kristin Skaar, Todd C. Van Driest, Sara L. Cavallari, Larisa H. Tuteja, Sony |
author_sort | Salloum, Ramzi G. |
collection | PubMed |
description | BACKGROUND: Despite the increased demand for pharmacogenetic (PGx) testing to guide antidepressant use, little is known about how to implement testing in clinical practice. Best–worst scaling (BWS) is a stated preferences technique for determining the relative importance of alternative scenarios and is increasingly being used as a healthcare assessment tool, with potential applications in implementation research. We conducted a BWS experiment to evaluate the relative importance of implementation factors for PGx testing to guide antidepressant use. METHODS: We surveyed 17 healthcare organizations that either had implemented or were in the process of implementing PGx testing for antidepressants. The survey included a BWS experiment to evaluate the relative importance of Consolidated Framework for Implementation Research (CFIR) constructs from the perspective of implementing sites. RESULTS: Participating sites varied on their PGx testing platform and methods for returning recommendations to providers and patients, but they were consistent in ranking several CFIR constructs as most important for implementation: patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and identification of champions. CONCLUSIONS: This study demonstrates the feasibility of using choice experiments to systematically evaluate the relative importance of implementation determinants from the perspective of implementing organizations. BWS findings can inform other organizations interested in implementing PGx testing for mental health. Further, this study demonstrates the application of BWS to PGx, the findings of which may be used by other organizations to inform implementation of PGx testing for mental health disorders. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43058-022-00300-7. |
format | Online Article Text |
id | pubmed-9107643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91076432022-05-16 Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy Salloum, Ramzi G. Bishop, Jeffrey R. Elchynski, Amanda L. Smith, D. Max Rowe, Elizabeth Blake, Kathryn V. Limdi, Nita A. Aquilante, Christina L. Bates, Jill Beitelshees, Amber L. Cipriani, Amber Duong, Benjamin Q. Empey, Philip E. Formea, Christine M. Hicks, J. Kevin Mroz, Pawel Oslin, David Pasternak, Amy L. Petry, Natasha Ramsey, Laura B. Schlichte, Allyson Swain, Sandra M. Ward, Kristen M. Wiisanen, Kristin Skaar, Todd C. Van Driest, Sara L. Cavallari, Larisa H. Tuteja, Sony Implement Sci Commun Short Report BACKGROUND: Despite the increased demand for pharmacogenetic (PGx) testing to guide antidepressant use, little is known about how to implement testing in clinical practice. Best–worst scaling (BWS) is a stated preferences technique for determining the relative importance of alternative scenarios and is increasingly being used as a healthcare assessment tool, with potential applications in implementation research. We conducted a BWS experiment to evaluate the relative importance of implementation factors for PGx testing to guide antidepressant use. METHODS: We surveyed 17 healthcare organizations that either had implemented or were in the process of implementing PGx testing for antidepressants. The survey included a BWS experiment to evaluate the relative importance of Consolidated Framework for Implementation Research (CFIR) constructs from the perspective of implementing sites. RESULTS: Participating sites varied on their PGx testing platform and methods for returning recommendations to providers and patients, but they were consistent in ranking several CFIR constructs as most important for implementation: patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and identification of champions. CONCLUSIONS: This study demonstrates the feasibility of using choice experiments to systematically evaluate the relative importance of implementation determinants from the perspective of implementing organizations. BWS findings can inform other organizations interested in implementing PGx testing for mental health. Further, this study demonstrates the application of BWS to PGx, the findings of which may be used by other organizations to inform implementation of PGx testing for mental health disorders. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43058-022-00300-7. BioMed Central 2022-05-14 /pmc/articles/PMC9107643/ /pubmed/35568931 http://dx.doi.org/10.1186/s43058-022-00300-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Short Report Salloum, Ramzi G. Bishop, Jeffrey R. Elchynski, Amanda L. Smith, D. Max Rowe, Elizabeth Blake, Kathryn V. Limdi, Nita A. Aquilante, Christina L. Bates, Jill Beitelshees, Amber L. Cipriani, Amber Duong, Benjamin Q. Empey, Philip E. Formea, Christine M. Hicks, J. Kevin Mroz, Pawel Oslin, David Pasternak, Amy L. Petry, Natasha Ramsey, Laura B. Schlichte, Allyson Swain, Sandra M. Ward, Kristen M. Wiisanen, Kristin Skaar, Todd C. Van Driest, Sara L. Cavallari, Larisa H. Tuteja, Sony Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy |
title | Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy |
title_full | Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy |
title_fullStr | Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy |
title_full_unstemmed | Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy |
title_short | Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy |
title_sort | best–worst scaling methodology to evaluate constructs of the consolidated framework for implementation research: application to the implementation of pharmacogenetic testing for antidepressant therapy |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107643/ https://www.ncbi.nlm.nih.gov/pubmed/35568931 http://dx.doi.org/10.1186/s43058-022-00300-7 |
work_keys_str_mv | AT salloumramzig bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT bishopjeffreyr bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT elchynskiamandal bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT smithdmax bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT roweelizabeth bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT blakekathrynv bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT limdinitaa bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT aquilantechristinal bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT batesjill bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT beitelsheesamberl bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT ciprianiamber bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT duongbenjaminq bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT empeyphilipe bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT formeachristinem bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT hicksjkevin bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT mrozpawel bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT oslindavid bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT pasternakamyl bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT petrynatasha bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT ramseylaurab bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT schlichteallyson bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT swainsandram bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT wardkristenm bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT wiisanenkristin bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT skaartoddc bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT vandriestsaral bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT cavallarilarisah bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy AT tutejasony bestworstscalingmethodologytoevaluateconstructsoftheconsolidatedframeworkforimplementationresearchapplicationtotheimplementationofpharmacogenetictestingforantidepressanttherapy |